[1] Grant S W, Collins G S, Nashef S A M. Statistical Primer:Developing and validating a risk prediction model[J]. European Journal of Cardio-Thoracic Surgery, 2018, 54(2):203-208.
[2] Hippisley-Cox J, Coupland C, Robson J, et al. Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease:Cohort study using QResearch database[J]. BMJ, 2010, 341:c6624.
[3] Collins G S, Reitsma J B, Altman D G, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD):The TRIPOD statement. The TRIPOD Group[J]. Circulation, 2015, 131(2):211-219.
[4] Patzer R E, Kaji A H, Fong Y. TRIPOD reporting guidelines for diagnostic and prognostic studies[J]. JAMA Surgery, 2021, 156(7):675-676.
[5] Moons K G M, Wolff R F, Riley R D, et al. PROBAST:A tool to assess risk of bias and applicability of prediction model studies:Explanation and elaboration[J]. Annals of Internal Medicine, 2019, 170(1):W1-W33.
[6] Davis S E, Lasko T A, Chen G H, et al. Calibration drift in regression and machine learning models for acute kidney injury[J]. Journal of the American Medical Informatics Association, 2017, 24(6):1052-1061.
[7] Greene T, Li L. From static to dynamic risk prediction:Time is everything[J]. American Journal of Kidney Diseases, 2017, 69(4):492-494.
[8] Tangri N, Inker L A, Hiebert B, et al. A dynamic predictive model for progression of CKD[J]. American Journal of Kidney Diseases, 2017, 69(4):514-520.
[9] Pan Z C, Zhang R Y, Shen S P, et al. OWL:An optimized and independently validated machine learning prediction model for lung cancer screening based on the UK Biobank, PLCO, and NLST populations[J]. EBioMedicine, 2023, 88:104443.
[10] Davis A M, Cifu A S. Lung cancer screening[J]. JAMA, 2014, 312(12):1248.
[11] Tammemägi M C, Ruparel M, Tremblay A, et al. USPSTF2013 versus PLCO m2012 lung cancer screening eligibility criteria (International Lung Screening Trial):Interim analysis of a prospective cohort study[J]. The Lancet Oncology, 2022, 23(1):138-148.
[12] Wang F, Tan F W, Shen S P, et al. Risk-stratified approach for never-and ever-smokers in lung cancer screening:A prospective cohort study in China[J]. American Journal of Respiratory and Critical Care Medicine, 2023, 207(1):77-88.
[13] Shen H B, Zhu M, Wang C. Precision oncology of lung cancer:Genetic and genomic differences in Chinese population[J]. NPJ Precision Oncology, 2019, 3:14.
[14] Hong W, Li A, Liu Y H, et al. Clonal hematopoiesis mutations in patients with lung cancer are associated with lung cancer risk factors[J]. Cancer Research, 2022, 82(2):199-209.
[15] Irajizad E, Fahrmann J F, Marsh T, et al. Mortality benefit of a blood-based biomarker panel for lung cancer on the basis of the prostate, lung, colorectal, and ovarian cohort[J]. Journal of Clinical Oncology, 2023, 41(27):4360-4368.
[16] Bos L D J, Sjoding M, Sinha P, et al. Longitudinal respiratory subphenotypes in patients with COVID-19-related acute respiratory distress syndrome:Results from three observational cohorts[J]. The Lancet Respiratory Medicine, 2021, 9(12):1377-1386.
[17] Haines R W, Zolfaghari P, Wan Y Z, et al. Elevated urea-to-creatinine ratio provides a biochemical signature of muscle catabolism and persistent critical illness after major trauma[J]. Intensive Care Medicine, 2019, 45(12):1718-1731.
[18] Ye Q, Wang X, Xu X S, et al. Serial platelet count as a dynamic prediction marker of hospital mortality among septic patients[J]. Burns & Trauma, 2024,12:tkae016.
[19] Tu Y K, Tilling K, Sterne J A C, et al. A critical evaluation of statistical approaches to examining the role of growth trajectories in the developmental origins of health and disease[J]. International Journal of Epidemiology, 2013, 42(5):1327-1339.
[20] Leffondré K, Abrahamowicz M, Regeasse A, et al. Statistical measures were proposed for identifying longitudinal patterns of change in quantitative health indicators[J]. Journal of Clinical Epidemiology, 2004, 57(10):1049-1062.
[21] Laird N M, Ware J H. Random-effects models for longitudinal data[J]. Biometrics, 1982, 38(4):963-974.
[22] Nguena Nguefack H L, Pagé M G, Katz J, et al. Trajectory modelling techniques useful to epidemiological research:A comparative narrative review of approaches[J]. Clinical Epidemiology, 2020, 12:1205-1222.
[23] Thurston R C, Chang Y F, Kline C E, et al. Trajectories of sleep over midlife and incident cardiovascular disease events in the study of women's health across the nation[J]. Circulation, 2024, 149(7):545-555.
[24] Muthén B, Shedden K. Finite mixture modeling with mixture outcomes using the EM algorithm[J]. Biometrics, 1999, 55(2):463-469.
[25] Feldman B J, Masyn K E, Conger R D. New approaches to studying problem behaviors:A comparison of methods for modeling longitudinal, categorical adolescent drinking data[J]. Developmental Psychology, 2009, 45(3):652-676.
[26] Muthén B. Latent variable hybrids:Overview of old and new models[J]. Advances in latent variable mixture models, 2008, 1:1-24.
[27] Muthén B, Asparouhov T. Growth mixture modeling with non-normal distributions[J]. Statistics in Medicine, 2015, 34(6):1041-1058.
[28] Wei Y H. Review for Dynamic Prediction in Clinical Survival Analysis[J/OL].[2023-11-27]. https://arxiv.org/abs/2311.15743.
[29] Little R J A, Rubin D B. Nonignorable missing-data models[M]. Hoboken:John Wiley & Sons, Inc., 2014.
[30] Wu L, Liu W, Yi G Y, et al. Analysis of longitudinal and survival data:Joint modeling, inference methods, and issues[J]. Journal of Probability and Statistics, 2012, 2012:1-17.
[31] Wulfsohn M S, Tsiatis A A. A joint model for survival and longitudinal data measured with error[J]. Biometrics, 1997, 53(1):330-339.
[32] Tsiatis A A, DeGruttola V, Wulfsohn M S. Modeling the relationship of survival to longitudinal data measured with error. applications to survival and CD4 counts in patients with AIDS[J]. Journal of the American Statistical Association, 1995, 90(429):27.
[33] Parr H, Hall E, Porta N. Joint models for dynamic prediction in localised prostate cancer:A literature review[J]. BMC Medical Research Methodology, 2022, 22(1):245.
[34] Chesnaye N C, Tripepi G, Dekker F W, et al. An introduction to joint models-applications in nephrology[J]. Clinical Kidney Journal, 2020, 13(2):143-149.
[35] Zhang T H, Tang X C, Zhang Y, et al. Multivariate joint models for the dynamic prediction of psychosis in individuals with clinical high risk[J]. Asian Journal of Psychiatry, 2023, 81:103468.
[36] Hennessey V, Novelo L L, Li J, et al. A Bayesian joint model for longitudinal DAS28 scores and competing risk informative drop out in a rheumatoid arthritis clinical trial[J/OL].[2018-01-25]. https://arxiv.org/abs/1801.08628.
[37] Chen M H, Ibrahim J G, Sinha D. A new joint model for longitudinal and survival data with a cure fraction[J]. Journal of Multivariate Analysis, 2004, 91(1):18-34.
[38] Chi Y Y, Ibrahim J G. Bayesian approaches to joint longitudinal and survival models accommodating both zero and nonzero cure fractions[J]. Statistica Sinica, 2007, 17:445-462.
[39] Andrinopoulou E R, Nasserinejad K, Szczesniak R, et al. Integrating latent classes in the Bayesian shared parameter joint model of longitudinal and survival outcomes[J]. Statistical Methods in Medical Research, 2020, 29(11):3294-3307.
[40] Garre F G, Zwinderman A H, Geskus R B, et al. A joint latent class changepoint model to improve the prediction of time to graft failure[J]. Journal of the Royal Statistical Society Series A:Statistics in Society, 2008, 171(1):299-308.
[41] Li K, Luo S. Dynamic predictions in Bayesian functional joint models for longitudinal and time-to-event data:An application to Alzheimer's disease[J]. Statistical Methods in Medical Research, 2019, 28(2):327-342.
[42] Li K, Luo S. Bayesian functional joint models for multivariate longitudinal and time-to-event data[J]. Computational Statistics & Data Analysis, 2019, 129:14-29.
[43] Köhler M, Umlauf N, Greven S. Nonlinear association structures in flexible Bayesian additive joint models[J]. Statistics in Medicine, 2018, 37(30):4771-4788.
[44] Köhler M, Umlauf N, Beyerlein A, et al. Flexible Bayesian additive joint models with an application to type 1 diabetes research[J]. Biometrical Journal Biometrische Zeitschrift, 2017, 59(6):1144-1165.
[45] Rizopoulos D. Joint models for longitudinal and time-toevent data:With applications in R[M]. Boca Raton:CRC Press, 2012.
[46] Huang X, Li G, Elashoff R M, et al. A general joint model for longitudinal measurements and competing risks survival data with heterogeneous random effects[J]. Lifetime Data Analysis, 2011, 17(1):80-100.
[47] Herle M, Micali N, Abdulkadir M, et al. Identifying typical trajectories in longitudinal data:Modelling strategies and interpretations[J]. European Journal of Epidemiology, 2020, 35(3):205-222.
[48] Proust-Lima C, Dartigues J F, Jacqmin-Gadda H. Joint modeling of repeated multivariate cognitive measures and competing risks of dementia and death:A latent process and latent class approach[J]. Statistics in Medicine, 2016, 35(3):382-398.
[49] 邱皓政. 潜在类别模型的原理与技术[M]. 北京:教育科学出版社, 2008.
[50] Nylund K L, Asparouhov T, Muthén B O. Deciding on the number of classes in latent class analysis and growth mixture modeling:A Monte Carlo simulation study[J]. Structural Equation Modeling:A Multidisciplinary Journal, 2007, 14(4):535-569.
[51] Larose C, Harel O, Kordas K, et al. Latent class analysis of incomplete data via an entropy-based criterion[J]. Statistical Methodology, 2016, 32:107-121.
[52] Han J, Slate E H, Peña E A. Parametric latent class joint model for a longitudinal biomarker and recurrent events[J]. Statistics in Medicine, 2007, 26(29):5285-5302.
[53] Proust-Lima C, Joly P, Dartigues J F, et al. Joint modelling of multivariate longitudinal outcomes and a time-toevent:A nonlinear latent class approach[J]. Computational Statistics & Data Analysis, 2009, 53(4):1142-1154.
[54] Beunckens C, Molenberghs G, Verbeke G, et al. A latent-class mixture model for incomplete longitudinal Gaussian data[J]. Biometrics, 2008, 64(1):96-105.
[55] Andrinopoulou E R, Rizopoulos D, Takkenberg J J,et al. Combined dynamic predictions using joint models of two longitudinal outcomes and competing risk data[J]. Statistical Methods In Medical Research, 2017, 26(4):1787-801.
[56] Hatfield L A, Boye M E, Carlin B P. Joint modeling of multiple longitudinal patient-reported outcomes and survival[J]. Journal of Biopharmaceutical Statistics, 2011, 21(5):971-991.
[57] He B, Luo S. Joint modeling of multivariate longitudinal measurements and survival data with applications to Parkinson's disease[J]. Statistical Methods in Medical Research, 2016, 25(4):1346-1358.
[58] Andrinopoulou E R, Rizopoulos D, Takkenberg J J M, et al. Joint modeling of two longitudinal outcomes and competing risk data[J]. Statistics in Medicine, 2014, 33(18):3167-3178.
[59] Taylor J M G, Yu M G, Sandler H M. Individualized predictions of disease progression following radiation therapy for prostate cancer[J]. Journal of Clinical Oncology, 2005, 23(4):816-825.
[60] Rizopoulos D, Hatfield L A, Carlin B P, et al. Combining dynamic predictions from joint models for longitudinal and time-to-event data using Bayesian model averaging[J]. Journal of the American Statistical Association, 2014, 109(508):1385-1397.
[61] Proust-Lima C, Taylor J M G. Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment PSA:A joint modeling approach[J]. Biostatistics, 2009, 10(3):535-549.
[62] Rizopoulos D. Dynamic predictions and prospective accuracy in joint models for longitudinal and time-to-event data[J]. Biometrics, 2011, 67(3):819-829.
[63] Proust-Lima C, Séne M, Taylor J M G, et al. Joint latent class models for longitudinal and time-to-event data:A review[J]. Statistical methods in medical research, 2014, 23(1):74-90.
[64] Rizopoulos D, Taylor J M G. Optimizing dynamic predictions from joint models using super learning[J]. Statistics in Medicine, 2024, 43(7):1315-1328.
[65] Barrett J K, Sweeting M J, Wood A M. Dynamic risk prediction for cardiovascular disease:An illustration using the ARIC study[M]//Handbook of Statistics. Amsterdam:Elsevier, 2017:47-65.
[66] McCrink L M, Marshall A H, Cairns K J. Advances in joint modelling:A review of recent developments with application to the survival of end stage renal disease patients[J]. International Statistical Review, 2013, 81(2):249-269.
[67] Zheng Y Y, Heagerty P J. Partly conditional survival models for longitudinal data[J]. Biometrics, 2005, 61(2):379-391.
[68] Keogh R H, Seaman S R, Barrett J K, et al. Dynamic prediction of survival in cystic fibrosis:A landmarking analysis using UK patient registry data[J]. Epidemiology, 2019, 30(1):29-37.
[69] Yang Z J, Hou Y W, Lyu J J, et al. Dynamic prediction and prognostic analysis of patients with cervical cancer:A landmarking analysis approach[J]. Annals of Epidemiology, 2020, 44:45-51.
[70] Yao Y, Li L, Astor B, et al. Predicting the risk of a clinical event using longitudinal data:The generalized landmark analysis[J]. BMC Medical Research Methodology, 2023, 23(1):5.
[71] Bull L M, Lunt M, Martin G P, et al. Harnessing repeated measurements of predictor variables for clinical risk prediction:A review of existing methods[J]. Diagnostic and Prognostic Research, 2020, 4:9.
[72] Chen Q, Tang B H, Song J Q, et al. Dynamic Bayesian network for predicting physiological changes, organ dysfunctions and mortality risk in critical trauma patients[J]. BMC Medical Informatics and Decision Making, 2022, 22(1):119.
[73] Marini S, Trifoglio E, Barbarini N, et al. A Dynamic Bayesian Network model for long-term simulation of clinical complications in type 1 diabetes[J]. Journal of Biomedical Informatics, 2015, 57:369-376.
[74] Orphanou K, Stassopoulou A, Keravnou E. DBN-extended:A dynamic Bayesian network model extended with temporal abstractions for coronary heart disease prognosis[J]. IEEE Journal of Biomedical and Health Informatics, 2016, 20(3):944-952.
[75] 国家统计局. 2022年中国卫生健康统计年鉴[M]. 北京:中国统计出版社, 2023.
[76] Allen B. The promise of explainable AI in digital health for precision medicine:A systematic review[J]. Journal of Personalized Medicine, 2024, 14(3):277.
[77] Luu M N, Han M J, Bui T T, et al. Smoking trajectory and cancer risk:A population-based cohort study[J]. Tobacco Induced Diseases, 2022, 20:71.
[78] You D F, Wang D H, Wu Y Q, et al. Associations of genetic risk, BMI trajectories, and the risk of non-small cell lung cancer:A population-based cohort study[J]. BMC Medicine, 2022, 20(1):203.
[79] Bui T T, Han M J, Luu N M, et al. Cancer risk according to alcohol consumption trajectories:A populationbased cohort study of 2.8 million Korean men[J]. Journal of Epidemiology, 2023, 33(12):624-632.
[80] Jarrett D, Yoon J, van der Schaar M. Dynamic prediction in clinical survival analysis using temporal convolutional networks[J]. IEEE Journal of Biomedical and Health Informatics, 2020, 24(2):424-436.
[81] Li C X, Zhao K, Zhang D F, et al. Prediction models of colorectal cancer prognosis incorporating perioperative longitudinal serum tumor markers:A retrospective longitudinal cohort study[J]. BMC Medicine, 2023, 21(1):63.
[82] Averbuch T, Sullivan K, Sauer A, et al. Applications of artificial intelligence and machine learning in heart failure[J]. The European Heart Journal-Digital Health, 2022, 3(2):311-322.
[83] Hunter D J, Holmes C. Where medical statistics meets artificial intelligence[J]. The New England Journal of Medicine, 2023, 389(13):1211-1219.
[84] Fihn S D, Berlin J A, Haneuse S J P A, et al. Prediction models and clinical outcomes:A call for papers[J]. JAMA Network Open, 2024, 7(4):e249640.
[85] Collins G S, Dhiman P, Ma J, et al. Evaluation of clinical prediction models (part 1):From development to external validation[J]. BMJ, 2024, 384:e074819.
[86] Riley R D, Snell K I E, Archer L, et al. Evaluation of clinical prediction models (part 3):Calculating the sample size required for an external validation study[J]. BMJ, 2024, 384:e074821.
[87] Riley R D, Archer L, Snell K I E, et al. Evaluation of clinical prediction models (part 2):How to undertake an external validation study[J]. BMJ, 2024, 384:e074820.